Gaddam Sainath, Nimmagadda Krishna C, Nagrani Tarun, Naqi Muniba, Wetz Robert V, Weiserbs Kera F, McCord Donald, Ghavami Foad, Gala Bhavesh, Lafferty James C
Department of Internal Medicine, Staten Island University Hospital, New York, USA.
Int Arch Med. 2011 Apr 28;4:14. doi: 10.1186/1755-7682-4-14.
In the setting of myocardial infarction (MI) or acute coronary syndrome (ACS), current guidelines recommend early and aggressive lipid lowering therapy with statins, irrespective of the baseline lipoprotein levels. Takotsubo cardiomyopathy (TCM) patients have a clinical presentation similar to myocardial infarction and thus receive early and aggressive statin therapy during their initial hospitalization. However, the pathology of TCM is not atherosclerotic coronary artery disease and hence we assumed the lipid profiles in TCM would be healthier than coronary artery disease patients.
In this retrospective study, we assessed fasting serum lipoprotein levels of ten TCM patients and compared them with forty, age and sex-matched myocardial infarction (MI) patients.
Comparing serum lipoprotein levels of TCM with MI group, there was no significant difference in mean total cholesterol between the two groups (174.5 mg/dL vs. 197.6 mg/dL, p = 0.12). However, in the TCM group, mean HDL-C was significantly higher (66.87 mg/dL vs. 36.5 mg/dL, p = 0.008), the mean LDL-C was significantly lower (89.7 mg/dL vs. 128.9 mg/dL, p = 0.0002), and mean triglycerides was also significantly lower (65.2 mg/dL vs. 166.8 mg/dL, p < 0.0001).
In this study, TCM patients in comparison to MI patients had significantly higher levels of HDL-C, lower levels of LDL-C levels and triglycerides. The lipid profiles in TCM were consistent with the underlying pathology of non-atherosclerotic, non-obstructive coronary artery disease. As lipoproteins in most TCM patients were within the optimal range, we recommend an individual assessment of lipid profiles along with their coronary heart disease risk factors for considering long term lipid-lowering therapy. A finding of hyperalphalipoproteinemia or hypotriglyceridemia in 40% of TCM patients is novel but this association needs to be confirmed in future studies with larger sample sizes. These findings may provide clues in understanding the pathogenesis of takotsubo cardiomyopathy.
在心肌梗死(MI)或急性冠状动脉综合征(ACS)的情况下,当前指南推荐早期积极使用他汀类药物进行降脂治疗,无论基线脂蛋白水平如何。应激性心肌病(TCM)患者的临床表现与心肌梗死相似,因此在初次住院期间接受早期积极的他汀类药物治疗。然而,TCM的病理并非动脉粥样硬化性冠状动脉疾病,因此我们推测TCM患者的血脂谱比冠状动脉疾病患者更健康。
在这项回顾性研究中,我们评估了10例TCM患者的空腹血清脂蛋白水平,并将其与40例年龄和性别匹配的心肌梗死(MI)患者进行比较。
将TCM患者与MI组的血清脂蛋白水平进行比较,两组的平均总胆固醇无显著差异(174.5mg/dL对197.6mg/dL,p=0.12)。然而,在TCM组中,平均高密度脂蛋白胆固醇(HDL-C)显著更高(66.87mg/dL对36.5mg/dL,p=0.008),平均低密度脂蛋白胆固醇(LDL-C)显著更低(89.7mg/dL对128.9mg/dL,p=0.0002),平均甘油三酯也显著更低(65.2mg/dL对166.8mg/dL,p<0.0001)。
在本研究中,与MI患者相比,TCM患者的HDL-C水平显著更高,LDL-C水平和甘油三酯水平更低。TCM患者的血脂谱与非动脉粥样硬化、非阻塞性冠状动脉疾病的潜在病理一致。由于大多数TCM患者的脂蛋白水平处于最佳范围内,我们建议对血脂谱及其冠心病危险因素进行个体评估,以考虑长期降脂治疗。40%的TCM患者出现高α脂蛋白血症或低甘油三酯血症这一发现很新颖,但这种关联需要在未来更大样本量的研究中得到证实。这些发现可能为理解应激性心肌病的发病机制提供线索。